Compare DexCom, Inc. (DXCM) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Skyworks Solutions Inc — how do they compare? DexCom, Inc. trades at $77.71 (market cap $28.06B), while Skyworks Solutions Inc trades at $57.21 (market cap $8.65B). The key difference: DexCom, Inc. is far larger — about 3.2× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays a 4.94% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SWKS | |
|---|---|---|
Market Cap | $28.06B | $8.65B |
Sector | Health | Technology |
52-Week High | $89.53 | $83.40 |
52-Week Low | $54.84 | $52.50 |
Enterprise Value | $27.03B | $8.42B |
Dividend Yield | — | 4.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Skyworks Solutions (SWKS) trades at $56.11, down 0.83% on the day, with a bearish technical signal but oversold RSI levels. The company reported Q1 2026 EPS of $1.15, beating estimates, and maintains a dividend yield above 4%. Revenue has declined from $5.5B in 2022 to $4.09B in 2025, though profitability metrics like a 41.08% gross margin remain solid. Recent news highlights product launches in EV and AI infrastructure, alongside ongoing legal investigations.
The stock presents a mixed outlook: analyst consensus is bullish with a $72.56 price target (29% upside), but technicals and declining revenue pose near-term risks. Opportunities include diversification beyond mobile chips and AI-driven demand, while risks involve customer concentration, margin pressure, and legal overhangs. Cash flow volatility and competitive threats require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
